1106 studies found for:    Ovarian Cancer: Clinical Trials
Show Display Options
Rank Status Study
21 Recruiting The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
Condition: Ovarian Cancer (Epithelial)
Intervention: Radiation: involved-field radiation therapy
22 Completed A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: ABT-888;   Drug: pegylated liposomal doxorubicin;   Drug: temozolomide
23 Recruiting Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.
Condition: Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors
Intervention: Drug: Orteronel 300mg BID
24 Completed
Has Results
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: Pemetrexed - Phase 1;   Drug: Carboplatin - Phase 1;   Drug: Pemetrexed - Phase 2;   Drug: Carboplatin - Phase 2
25 Recruiting A Clinical Trial in Patients With BRCA Defective Tumours
Conditions: Breast Cancer;   Ovarian Cancer
Interventions: Drug: 6-Mercaptopurine;   Drug: Methotrexate
26 Completed Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
Conditions: Platinum Refractory Epithelial Ovarian Cancer;   Primary Cancer of the Peritoneum;   Cancer of the Fallopian Tube
Interventions: Drug: Sunitinib;   Drug: SUNITINIB
27 Recruiting EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Paclitaxel + Carboplatin every 3 weeks;   Drug: Carboplatin monotherapy every 3 weeks;   Drug: Weekly Paclitaxel and Carboplatin
28 Completed
Has Results
Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Bendamustine HCL
29 Recruiting Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Biological: FANG™
30 Withdrawn CA-125 in Screening Patients at High Risk for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Other: physiologic testing;   Procedure: study of high risk factors
31 Active, not recruiting Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Fallopian Cancer;   Peritoneal Cancer
Interventions: Biological: E39 peptide vaccine;   Other: Clinical tracking for disease progression/recurrence
32 Terminated Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer;   Bowel Obstruction
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
33 Completed GM-CSF in Women With Recurrent Ovary Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: GM-CSF, Leukine
34 Not yet recruiting Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer
Conditions: Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer
Interventions: Other: palliative care;   Behavioral: educational intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Behavioral: telephone-based intervention
35 Unknown  A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Biological: OC-L/Montanide ISA 51 VG;   Biological: Ampligen;   Biological: Prevnar
36 Recruiting Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pimasertib once daily;   Drug: Pimasertib placebo;   Drug: SAR245409  placebo;   Drug: SAR245409;   Drug: Pimasertib twice daily
37 Recruiting A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Conditions: Prostate Cancer;   Salivary Gland Cancer;   Endometrial Cancer;   Squamous Cell Carcinoma of the Cervix;   Breast Cancer;   Ovarian Cancer
Intervention: Drug: OPB-111001
38 Recruiting Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Condition: Ovarian Cancer
Intervention: Drug: IMAB027
39 Completed Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin
40 Unknown  Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: Paclitaxel+Carboplatin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years